[Antidepressants and suicidality: primum non nocere]

Area of Science:

• Psychiatry and Mental Health
• Clinical Pharmacology

Context:

• International health agencies issued warnings regarding antidepressant use in pediatric populations since 2003, extended to young adults in 2007.
• These warnings stemmed from clinical trial data indicating an elevated risk of suicidality.
• The widespread prescription of antidepressants has made these warnings a subject of significant controversy and research.

Purpose:

• To review the existing clinical trial data and identify challenges in evaluating the relationship between antidepressant use and suicidality in children and adolescents.
• To clarify the complexities surrounding the diagnosis of depression in pediatric populations, including high rates of bipolarity.
• To differentiate between antidepressant-induced activation syndrome and mixed states, both associated with suicide risk.

Summary:

• Reports indicate a potential increase in suicide attempts during the initial phase of antidepressant treatment.
• Current evidence does not support an increase in completed suicide rates associated with antidepressant therapy.
• Methodological challenges in defining "suicidality" and evaluating suicide risk complicate research findings.

Impact:

• Highlights the critical need for accurate diagnosis and vigilant patient monitoring in managing depression, irrespective of pharmacological intervention.
• Informs clinicians and regulatory bodies about the nuanced risks and benefits of antidepressant treatment in young populations.
• Underscores the importance of continued research to refine diagnostic criteria and improve the assessment of suicide risk in pediatric mental health care.